347 related articles for article (PubMed ID: 19512961)
1. Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial.
Pae CU; Marks DM; Masand PS; Peindl K; Hooper-Wood C; Han C; Mannelli P; Ciccone P; Patkar AA
Clin Neuropharmacol; 2009; 32(2):85-8. PubMed ID: 19512961
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
[TBL] [Abstract][Full Text] [Related]
3. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Harpold T; Dunkel S; Dougherty M; Aleardi M; Spencer T
Biol Psychiatry; 2006 May; 59(9):829-35. PubMed ID: 16373066
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
[TBL] [Abstract][Full Text] [Related]
5. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Medori R; Ramos-Quiroga JA; Casas M; Kooij JJ; Niemelä A; Trott GE; Lee E; Buitelaar JK
Biol Psychiatry; 2008 May; 63(10):981-9. PubMed ID: 18206857
[TBL] [Abstract][Full Text] [Related]
6. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
7. Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate.
Buitelaar JK; Kooij JJ; Ramos-Quiroga JA; Dejonckheere J; Casas M; van Oene JC; Schäuble B; Trott GE
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):554-60. PubMed ID: 21185347
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial.
Lower EE; Fleishman S; Cooper A; Zeldis J; Faleck H; Yu Z; Manning D
J Pain Symptom Manage; 2009 Nov; 38(5):650-62. PubMed ID: 19896571
[TBL] [Abstract][Full Text] [Related]
9. Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury.
Lee H; Kim SW; Kim JM; Shin IS; Yang SJ; Yoon JS
Hum Psychopharmacol; 2005 Mar; 20(2):97-104. PubMed ID: 15641125
[TBL] [Abstract][Full Text] [Related]
10. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
Ramos-Quiroga JA; Corominas M; Castells X; Bosch R; Casas M
Expert Rev Neurother; 2009 Aug; 9(8):1121-31. PubMed ID: 19673602
[TBL] [Abstract][Full Text] [Related]
11. Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD.
Kim Y; Shin MS; Kim JW; Yoo HJ; Cho SC; Kim BN
Hum Psychopharmacol; 2009 Mar; 24(2):95-102. PubMed ID: 19226534
[TBL] [Abstract][Full Text] [Related]
12. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.
Ravindran AV; Kennedy SH; O'Donovan MC; Fallu A; Camacho F; Binder CE
J Clin Psychiatry; 2008 Jan; 69(1):87-94. PubMed ID: 18312042
[TBL] [Abstract][Full Text] [Related]
13. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.
Mendonça DA; Menezes K; Jog MS
Mov Disord; 2007 Oct; 22(14):2070-6. PubMed ID: 17674415
[TBL] [Abstract][Full Text] [Related]
14. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy.
Butler JM; Case LD; Atkins J; Frizzell B; Sanders G; Griffin P; Lesser G; McMullen K; McQuellon R; Naughton M; Rapp S; Stieber V; Shaw EG
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1496-501. PubMed ID: 17869448
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
[TBL] [Abstract][Full Text] [Related]
16. Female sexual dysfunction related to depression and antidepressant medications.
Clayton AH
Curr Womens Health Rep; 2002 Jun; 2(3):182-7. PubMed ID: 12099193
[TBL] [Abstract][Full Text] [Related]
17. Effect of methylphenidate and/or levodopa combined with physiotherapy on mood and cognition after stroke: a randomized, double-blind, placebo-controlled trial.
Delbari A; Salman-Roghani R; Lokk J
Eur Neurol; 2011; 66(1):7-13. PubMed ID: 21701174
[TBL] [Abstract][Full Text] [Related]
18. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users.
Parasrampuria DA; Schoedel KA; Schuller R; Silber SA; Ciccone PE; Gu J; Sellers EM
J Clin Psychopharmacol; 2007 Oct; 27(5):459-67. PubMed ID: 17873677
[TBL] [Abstract][Full Text] [Related]
19. Switching to tianeptine in patients with antidepressant-induced sexual dysfunction.
Atmaca M; Kuloglu M; Tezcan E; Buyukbayram A
Hum Psychopharmacol; 2003 Jun; 18(4):277-80. PubMed ID: 12766932
[TBL] [Abstract][Full Text] [Related]
20. PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study.
Dinsmore WW; Wyllie MG
BJU Int; 2009 Apr; 103(7):940-9. PubMed ID: 19245438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
